Trial Profile

A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NKX 019 (Primary) ; Cyclophosphamide; Fludarabine
Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Myositis; Systemic scleroderma
Focus Therapeutic Use
Acronyms Ntrust-2
Sponsors Nkarta Therapeutics

10 Nov 2025 According to a Nkarta Therapeutics Media Release, preliminary clinical data are expected to be presented at a medical conference in 2026.
28 Oct 2025 Planned number of patients changed from 72 to 144.
14 May 2025 Protocol was amended to to modify lymphodepletion prior to administration of NKX019 to use of a combination of fludarabine and cyclophosphamide, with the option for eligible patients to continue to receive cyclophosphamide alone as modified lymphodepletion.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com